Join
Live feed
·
PRReleasevia Quantisnow
Forte Biosciences Inc. logo

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

ByQuantisnow·Wall Street's wire, on your screen.
FBRX· Forte Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FBRX (Forte Biosciences Inc.) and more on Quantisnow.